GUIDEWIRE-SOFTWARE-INC
4.10.2021 11:32:11 CEST | Business Wire | Press release
Guidewire Software, Inc. (NYSE: GWRE), today announced that it has been positioned as a Leader in Gartner, “Gartner Magic Quadrant for Non-Life Insurance Platforms, Europe1 ” . Guidewire was placed highest on the ability to execute axis and furthest on the completeness of vision axis. This is the fourth year that Gartner has produced a Magic Quadrant for Non-Life Insurance Platforms, Europe, and it marks the fourth year that Guidewire has been named a Leader. A complimentary copy of the report can be viewed here .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211004005396/en/
“Leaders have the highest combined scores for Ability to Execute and Completeness of Vision. They have a thorough market understanding, a strong non-life-insurance industry focus, and a clearly articulated vision for the future of the market and their products. Leaders offer technically solid and functionally complete software products. They have proven implementation track records with an adequate installed base,” according to the Gartner report.
“We are honoured to be recognised by Gartner for the fourth year in a row as a Leader in its Magic Quadrant for Non-Life Insurance Platforms, Europe,” said Laurent Fontaine, group vice president, Sales, EMEA, Guidewire Software. “We are committed to leading technology innovation in the non-life insurance industry and are setting the bar with our cloud-optimised platform. Customer success remains our top priority and we embrace those insurers seeking to modernise their legacy infrastructures and those wanting to test cloud by quickly bringing new business to market via a greenfield approach.”
Guidewire’s momentum with InsuranceSuite during 2020 – 2021 includes:
- Twice yearly releases of the Guidewire platform (Aspen and Banff in 2020, and Cortina so far in 2021), delivered as a cloud service, to accelerate innovation. Complex upgrades are a thing of the past, and operation and maintenance burdens are transferred to Guidewire.
- Delivery of Guidewire Cloud Platform which provides a Guidewire-engineered architecture for the cloud. It includes infrastructure, application services, and data services and enables the provisioning, scalability, and security of Guidewire cloud products.
- The reimagined Guidewire core platform with embedded analytics and native support for digital experiences for customers, agents, and employees — the most complete P&C insurance platform in the world.
- The industry’s first smart-loop analytics platform which enables improved understanding of risk signal, more automated processes, better decision-making, a better customer experience, and improved business intelligence.
- A complete set of APIs and integration tools, along with a world-class developer experience, that accelerate innovation while making it easier to integrate with other systems and build add-ons through a growing Guidewire Marketplace .
- Product functional completeness, tooling, and methodology to continually drive down the cost of implementing and operating the Guidewire platform.
*Additional Recognition:
- Magic Quadrant for P&C Core Platforms, North America, named a Leader seven consecutive times*
1
Gartner, Magic Quadrant for Non-Life Insurance Platforms, Europe, James Ingham
, Sham Gill
, 27 September 2021
Gartner, Magic Quadrant for P&C Core Platforms, North America, James Ingham
, Sham Gill
,14 September 2021
Gartner and Magic Quadrant are registered trademarks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.
Disclaimer
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About Guidewire
Guidewire is the platform general insurers trust to engage, innovate, and grow efficiently. We combine digital, core, analytics, and AI to deliver our platform as a cloud service. More than 400 insurers, from new ventures to the largest and most complex in the world, run on Guidewire.
As a partner to our customers, we continually evolve to enable their success. We are proud of our unparalleled implementation track record, with 1,000+ successful projects, supported by the largest R&D team and partner ecosystem in the industry. Our marketplace provides hundreds of applications that accelerate integration, localization, and innovation.
For more information, please visit www.guidewire.com and follow us on twitter: @Guidewire_PandC .
NOTE: For information about Guidewire’s trademarks, visit https://www.guidewire.com/legal-notices .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211004005396/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom